Poli Group Holding SRL
Latest From Poli Group Holding SRL
Among Europe’s flourishing niche of mid-sized pharmaceutical companies, Italy’s Recordati and Spain’s Almirall have snapped up smaller local companies during the past six to nine months, while Switzerland’s Actelion is concentrating on executing new product launches while considering M&A.
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.